Abstract
Palmoplantar psoriasis (PP) is a special area of psoriasis, which can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase (IPDE)-4 that has been recently approved by FDA as a cream for the treatment of plaque psoriasis. Also, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis in a small randomized clinical trial and single case reports. To the best of our knowledge, we present the first case series of PP treated with oral roflumilast.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
